Strategic targets of essential host-pathogen interactions

Respiration

Volumn 72, Issue 1, 2005, Pages 9-25

  Blasi, Francesco ^a   Tarsia, Paolo ^a   Aliberti, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antimicrobial peptides; Innate immunity; Surfactant proteins; Toll like receptors

Indexed keywords

ANTIBIOTIC AGENT; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BETA DEFENSIN 1; C REACTIVE PROTEIN; CATHELICIDIN; COLLECTIN; COMPLEMENT; CYTOKINE; DEFENSIN; ELAFIN; FURANONE DERIVATIVE; HEPCIDIN; HISTATIN; INDOLICIDIN; LACTOFERRIN; LYSOZYME; MANNOSE; MANNOSE BINDING LECTIN; NEUROPEPTIDE; POLYPEPTIDE; PROTEIN; RECEPTOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR;

AIRWAY; ALLERGIC REACTION; BASOPHIL; BIOLOGY; CLINICAL TRIAL; DISEASE SEVERITY; ENZYME ACTIVITY; EOSINOPHIL; GENE FUNCTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INFECTION RISK; INFLAMMATION; LUNG INFECTION; MACROPHAGE; MAST CELL; MEDIATOR; MICROORGANISM; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; MOLECULE; MONOCYTE; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; REVIEW; RISK ASSESSMENT; SECRETION; SIGNAL TRANSDUCTION;

ANIMALS; BACTERIA; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; PHAGOCYTES; PHAGOCYTOSIS; PNEUMONIA, BACTERIAL; PULMONARY ALVEOLI;

EID: 16344373478     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083394     Document Type: Review

References (139)

1. Medzhitov R, Janeway CA: Innate immunity: Impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9.
2. Delves PJ, Roitt IM: The immune system. N Engl J Med 2000;343:37-49.
3. Medzhitov R, Janeway CA: Innate immunity. N Engl J Med 2000;343:338-344.
4. Turner MW, Hamvas RMJ: Mannose-binding lectin: Structure, function, genetics and disease associations. Rev Immunogenet 2002;2:305-322.
5. Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T: Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 2000;165:2637-2642.
6. Madsen HO, Garred P, Kurtzhals JAL, Lamm LU. Ryder LP, Thiel S, Svejgaard A: A new frequent allele is the missing link in the structural polymorphism of the human mannanbinding protein. Immunogenetics 1994;40:37-44.
7. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A: Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein J Immunol 1995;155:3013-3020.
8. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, Hansen CH, Andersen LH, Hahn GW, Garred P: Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001;285:1316-1321.
9. Davies JC, Turner MW, Klein N: Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 2004;24:798-804.
10. Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, Smarason A, Day NP, McPheat WL, Crook DW, Hill AV: MBL genotype and risk of invasive pneumococcal disease: A case-control study. Lancet 2002;359:1569-1573.
11. Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis LA, Beyers N, Zurakowski D, Ezekowitz AB, Van Helden PD: Mannose-binding protein B allele confers protection against tuberculous meningitis. Pediatr Res 1999;45:459-464.
12. Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, Balstrup F, Koch C, Koch C: Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol 2002;33:201-207.
13. Fraser IP, Koziel H, Ezekowitz A: The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 1998;10:363-372.
14. Thomas CA, Li Y, Kodama T, Suzuki H, Silverstein SC, El Khoury J: Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J Exp Med 2000;191:147-156.
15. Savill J: Recognition and phagocytosis of cells undergoing apoptosis. Br Med Bull 1997;53:491-508.
16. Anderson KV, Jurgens G, Nusslein-Volhard C: Establishment of dorsal-ventral polarity in the Drosophila embryo: Genetic studies on the role of the Toll gene product. Cell 1985;42:779-789.
17. Lemaitre BE, Nicolas E, Michaut NL, Reichhart JM, Hoffmann JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983.
18. O'Neill LA, Greene C: Signal transduction pathways activated by the IL-1 receptor family: Ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 1998;63:650-657.
19. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, Golenbock DT: Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999;274:33419-33425.
20. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Liu YJ: Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-869.
21. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-738.
22. Beutler B: Tlr4: Central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000;12:20-26.
23. Ohashi K, Burkart V, Flohe S, Kolb H: Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 2000;164:558-561.
24. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1:398-401.
25. Fenton MJ, Golenbock DT: LPS-binding proteins and receptors. J Leukoc Biol 1998;64:25-32.
26. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS: Plasma CD14 decreases monocyte response to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001;108:485-493.
27. Miyake K: Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 2004;12:186-192.
28. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K: Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002;3:667-672.
29. Ohnishi T, Muroi M, Tanamoto K: MD-2 is necessary for the toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface. Clin Diagn Lab Immunol 2003;10:405-410.
30. Akashi S, Nagai Y, Ogata H, Oikawa M, Fukase K, Kusumoto S, Kawasaki K, Nishijima M, Hayashi S, Kimoto M, Miyake K: Human MD-2 confers on mouse toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol 2001;13:1595-1599.
31. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN: MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001;276:38044-38051.
32. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underbill DM, Aderem A: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;420:10991 1103.
33. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-744.
34. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S: Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001;13:933-940.
35. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, Takeda K, Akira S: Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002;420:324-329.
36. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z: MyD88: An adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7:837-847.
37. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC: Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 2002;416:750-756.
38. Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110:191-202.
39. O'Neill LA: Signal transduction pathways activated by the IL-1 receptor/Toll-like receptor superfamily. Curr Top Microbiol Immunol 2002;270:17-61.
40. Zhang G, Ghosh S: Toll-like receptor-mediated NF-κB activation: A phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107:13-19.
41. Diamond G, Kaiser V, Rhodes J, Russell JP, Bevins CL: Transcriptional regulation of beta-defensin gene expression in tracheal epithelial cells. Infect Immun 2000;68:113-119.
42. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000;18:621-663.
43. Kopp E, Medzhitov R, Carothers J, Xiao C, Douglas I, Janeway CA, Ghosh S: ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev 1999;13:2059-2071.
44. Chang L, Karin M: Mammalian MAP kinase signaling cascades. Nature 2001;420:37-40.
45. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S: TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003;4:1144-1150.
46. Cohen J: The immunopathogenesis of sepsis. Nature 2002;420:885-891.
47. Agrawal A: Different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003;171:4984-4989.
48. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J: Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003;197:403-411.
49. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A: Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 1999;285:736-739.
50. Netea MG, Van der Meer JW, Kuliberg BJ: Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol 2004;12:484-488.
51. Hashimoto M, Asai Y, Ogawa T: Treponemal phospholipids inhibit innate immune responses by pathogen-associated molecular patterns. J Biol Chem 2003;278:44205-44213.
52. Harte MT, Haga IR, Maloney G, Gray P, Reading PC, Bartlett NW. Smith GL, Bowie A, O'Neill LA: The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003;197:343-350.
53. Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM: Helicobacter pylori flagellin evades Toll-like receptor 5-mediated innate immunity. J Infect Dis 2004;189:1914-1920.
54. Sundstrom JB, Little DM, Villinger F, Ellis JE, Ansari AA: Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells. J Immunol 2004;172:4391-4399.
55. Iwami K, Matsuguchi T, Masada A, Kikuchi T, Musikacharoen T, Yoshikai Y: Cutting edge: Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2001;165:6682-6686.
56. Means TK, Golenbock DT, Fenton MJ: The biology of Toll-like receptors. Cytokine Growth Factor Rev 2000;11:219-232.
57. Yeh WC, Chen NJ: Another Toll road. Nature 2003;424:736-737.
58. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
59. Thompson D, Pepys MB, Wood SP: The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7:169-177.
60. Pepys MB, Hirschfield GM: C-reactive protein: A critical update. J Clin Invest 2003;111:1805-1812.
61. Knowles MR. Boucher RC: Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-577.
62. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC: The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 2001;118:223-236.
63. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G: Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-325.
64. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR: Effect of uridine 5-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996;153:1796-1801.
65. Zeitlin PL, Diener-West M, Rubinstein RC, Boyle MP, Lee CK, Brass-Ernst L: Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002;6:119-126.
66. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ: Curcumin, a major constituent of tumeric, corrects cystic fibrosis defects. Science 2004;304:600-602.
67. Wu H, Song Z, Hentzer M, Andersen JB, Molin S, Givskov M, Hoiby N: Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother 2004;53:1054-1061.
68. Zasloff M: Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-395.
69. Bals R: Epithelial antimicrobial peptides in host defense against infection. Respir Res 2000;1:141-150.
70. Ganz T: Epithelia: Not just physical barriers. Proc Natl Acad Sci USA 2002;99:3357-3358.
71. Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M: Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 2000;49:73-79.
72. Thompson AB, Bohling T, Payvandi F, Rennard SI: Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis. J Lab Clin Med 1990;115:148-158.
73. Ganz T: Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002;109:693-697.
74. Orsi N: The antimicrobial activity of lactoferrin: Current status and perspectives. Biometals 2004;17:189-196.
75. Zhu J, Nathan C, Ding A: Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor. Biochim Biophys Acta 1999;1451:219-223.
76. Simpson AJ, Maxwell AI, Govan JRW, Haslett C, Sallenave JM: Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS Lett 1999;452:309-313.
77. Canny G, Levy O, Furuta GT, Narravula-Alipati S, Sisson RB, Serhan CN, Colgan SP: Lipid mediator-induced expression of bactericidal/permeability- increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA 2002;99:3902-3907.
78. Levy O: Therapeutic potential of the bactericidal/permeability-increasing protein. Expert Opin Investig Drags 2002;11:159-167.
79. Andrault JB, Gaillard I, Giorgi D, Rouquier S: Expansion of the BPI family by duplication on human chromosome 20: Characterization of the RY gene cluster in 20q11.21 encoding olfactory transporters/antimicrobial-like peptides. Genomics 2003;82:172-184.
80. Bingle CD, Gorr SU: Host defense in oral and airway epithelia: Chromosome 20 contributes a new protein family. Int J Biochem Cell Biol 2004;36:2144-2152.
81. Lehrer R, Ganz T, Selsted M: Defensins: Endogenous antibiotic peptides of animal cells. Cell 1991;64:229-230.
82. Linzmeier R, Ho CH, Hoang BV, Ganz T: A 450-kb contig of defensin genes on human chromosome 8p23. Gene 1999;233:205-211.
83. Soong L, Ganz T, Ellison A, Caughey G: Purification and characterization of defensins from cystic fibrosis sputum. Inflamm Res 1997;46:98-102.
84. McCray P Jr, Bentley L: Human airway epithelia express a β-defensin. Am J Respir Cell Mol Biol 1997;16:343-349.
85. Becker MN, Diamond G, Verghese MW, Randell SH: CD 14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000;275:29731-29736.
86. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB Jr: Production of β-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998;95:14961-14966.
87. Dauletbaev N, Gropp R, Frye M, Loitsch S, Wagner TO, Bargon J: Expression of human β-defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals and individuals with acute colds. Respiration 2002;69:46-51.
88. Zanetti M, Gennaro R, Romeo D: Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995;374:1-5.
89. Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998;95:9541-9546.
90. Schaller-Bals S, Schulze A, Bals R: Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med 2002;165:992-995.
91. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM: Augmentation of innate host defence by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999;67:6084-6089.
92. van der Spek JC, Offner GD, Troxler RF, Oppenheim FG: Molecular cloning of human submandibular histatins. Arch Oral Biol 1990;35:137-143.
93. Gusman H, Travis J, Heimerhorst EJ, Potempa J, Troxler RF, Oppenheim FG: Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease. Infect Immun 2001;69:1402-1408.
94. Yang D, Biragyn A, Kwak LW, Oppenheim JJ: Mammalian defensins in immunity: More than just microbicidal. Trends Immunol 2002;23:291-296.
95. Van Wetering S, Mannesse-Lazeroms SP, Van Sterkenburg MA, Daha MR, Dijkman JH, Hiemstra PS: Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am J Physiol 1997;272:L888-L896.
96. Van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J, Hiemstra PS: Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol 2000;278:L51-58.
97. Van Wetering S, Rahman I, Hiemstra PS, MacNee W: Role of intracellular glutathione in neutrophil defensin-induced IL-8 synthesis and cytotoxicity in airway epithelial cells. Eur Respir J 1998;12:420s.
98. Aarbiou J, Ertmann M, van Wetering S, van Noort P, Rook D, Rabe KF, Litvinov SV, van Krieken JH, de Boer WI, Hiemstra PS: Human neutrophil defensins induce lung epithelial cell proliferation in vitro. J Leukoc Biol 2002;72:167-174.
99. Ganz T, Lehrer RI: Defensins. Pharmacol Ther 1995;66:191-205.
100. Gennaro R, Zanetti M: Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 2000;55:31-49.
101. Yang D, Chertov O, Bykovskaia S, Chen Q, Buffo M, Shogan J, Anderson M, Schroder J, Wang J, Howard O, Oppenheim J: β-Defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-528.
102. Devine DA: Antimicrobial peptides in defence of the oral and respiratory tracts. Mol Immunol 2003;40:431-443.
103. Peschel A: How do bacteria resist human antimicrobial peptides? Trends Microbiol 2002;10:179-186.
104. Lysenko ES, Gould J, Bals R, Wilson JM, Weiser JN: Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun 2000;68:1664-1671.
105. Potempa J, Babbula A, Travis J: Role of bacterial proteinases in matrix destruction and modulation of host responses. Periodontology 2000;24:153-192.
106. Schmidtchen A, Frick IM, Andersson E, Tapper H, Björk L: Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 2002;46:157-168.
107. Ganz T, Bellm L, Lehrer RI: Protegrins: New antibiotics of mammalian origin. Expert Opin Investig Drugs 2000;9:1731-1742.
108. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM: Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999;67:6084-89.
109. Bals R, Weiner DJ, Meegalla RL, Wilson JM: Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999;103:1113-1117.
110. Weidenmaier C, Kristian SA, Peschel A: Bacterial resistance to antimicrobial host defenses: An emerging target for novel antiinfective strategies? Curr Drug Targets 2003;4:643-649.
111. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
112. Lauth X, Babon JJ, Stannard JA, Singh S, Nizet V, Carlberg JM, Ostland VE, Pennington MW, Norton RS, Westerman ME: Bass hepcidin: Synthesis, solution structure, antimicrobial activities and synergism, and in vivo hepatic response to bacterial infections. J Biol Chem 2004 [Epub ahead of print].
113. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276.
114. Subbalakshmi C, Sitaram N: Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 1998;160:91-96.
115. Ryge TS, Doisy X, Ifrah D, Olsen JE, Hansen PR: New indolicidin analogues with potent antibacterial activity. J Pept Res 2004;64:171-185.
116. Lugardon K, Raffner R, Goumon Y, Corti A, Delmas A, Bulet P, Aunis D, Metz-Boutigue MH: Antibacterial and antifungal activities of vasostatin-I, the N-terminal fragment of chromogranin A. J Biol Chem 2000;275:10745-10753.
117. Goumon Y, Lugardon K, Kieffer B, Lefevre JF, Van Dorsselaer A, Aunis D, Metz-Boutigue MH: Characterization of antibacterial COOH-terminal proenkephalin-A-derived peptides (PEAP) in infectious fluids. Importance of enkelytin, the antibacterial PEAP209-237 secreted by stimulated chromaffin cells. J Biol Chem 1998;273:29847-29856.
118. Kieffer AE, Goumon Y, Ruh O, Chasserot-Golaz S, Nullans G, Gasnier C, Aunis D, Metz-Boutigue MH: The N- and C-terminal fragments of ubiquitin are important for antimicrobial activities. FASEB J 2003;17:776-778.
119. Metz-Boutigue MH, Kieffer AE, Goumon Y, Aunis D: Innate immunity: Involvement of new neuropeptides. Trends Microbiol 2003;11:585-592.
120. Wright JR: Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-962.
121. Atochina EN, Beck JM, Scanlon ST, Preston AM, Beers MF: Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J Lab Clin Med 2001;137:429-439.
122. Palaniyar N, Nadesalingam J, Reid KB: Innate immune collectins bind nucleic acids and enhance DNA clearance in vitro. Ann NY Acad Sci 2003;1010:467-470.
123. Khoor A, Gray ME, Hull WM, Whitsett JA, Stahlman MT: Developmental expression of SP-A and SP-A mRNA in the proximal and distal respiratory epithelium in the human fetus and newborn. J Histochem Cytochem 1993;41:1311-1319.
124. Le Vine AM, Whitsett JA: Pulmonary collectins and innate host defense of the lung. Microbes Infect 2001;3:161-166.
125. Korfhagen TR, Bruno MD, Ross GF, Huelsman KM, Ikegami M, Jobe AH, Wert SE, Stripp BR, Morris RE, Glasser SW, Bachurski CJ, Iwamoto HS, Whitsett JA: Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci USA 1996;93:9594-9599.
126. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR: Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol 1997;158:4336-4340.
127. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR: Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998;19:700-708.
128. LeVine AM, Gwozdz J, Stark J, Bruno MD, Whitsett JA, Korfhagen TA: Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 1999;103:1015-1021.
129. Gaynor CD, McCormack FX, Voelker DR, McGowan SE, Schlesinger LS: Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J Immunol 1995;155:5343-5351.
130. LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, Korfhagen TR: Distinct effects of surfactant protein A and D deficiency during bacterial infection on the lung. J Immunol 2000;165:3934-3940.
131. Madsen J, Kliem A, Tornoe I, Skjodt K, Koch C, Holmskov TJ: Localization of lung surfactant protein D on mucosal surfaces in human tissue. J Immunol 2000;164:5866-5870.
132. Van Iwaarden JF, Pikaar JC, Storm J, Brouwer E, Verhoef J, Oosting RS, van Golde LM, van Strijp JA: Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides. Biochem J 1994;303:407-411.
133. Restrepo CI, Dong Q, Savov J, Mariencheck WI, Wright JR: Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Respir Cell Mol Biol 1999;21:576-585.
134. Hartshorn KL, Crouch E, White MR, Colamussi ML, Kakkanatt A, Tauber B, Shepherd V, Sastry KN: Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol 1998;274:L958-L969.
135. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM: By binding SIRP α or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003;115:13-23.
136. Ferguson JS, Voelker DR, Ufnar JA, Dawson AJ, Schlesinger LS: Surfactant protein D inhibition of human macrophage uptake of Mycobacterium tuberculosis is independent of bacterial agglutination. J Immunol 2002;168:1309-1314.
137. 7 Hickling TP, Malhotra R, Bright H, McDowell W, Blair ED, Sim RB: Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells. Viral Immunol 2000;13:125-135.
138. Schaeffer LM, McCormack FX, Wu H, Weiss AA: Interactions of pulmonary collectins with Bordetella bronchiseptica and Bordetella pertussis lipopolysaccharide elucidate the structural basis of their antimicrobial activities. Infect Immun 2004;72:7124-7130.
139. van de Wetering JK, van Golde LM, Batenburg JJ: Collectins: Players of the innate immune system. Eur J Biochem 2004;271:1229-1249.